Animals Feed Market | Increasing Number of Product Launches to Boost the Market Growth

The global animals feed market size is poised to grow by USD 92.79 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005424/en/

Technavio has announced its latest market research report titled Global Animal Feed Market 2020-2024 (Graphic: Business Wire)

The increasing number of product launches will be a significant factor in driving the growth of the animal feed market size. The global animal feed market is witnessing a growing number of product launches by vendors operating in the market. For instance, MilkLane launched two variants of animal feed, namely Aayush Max and Aayush Rich, containing proteins and minerals, which will improve animal health and increasing milk yield. Nutreco also launched two fish feed products suitable for tilapia under the brand Skretting. The successful launch of such new products will help market vendors to increase their revenue flow and market share and consequently drive the growth of the animal feed market during the forecast period.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major animals feed market growth came from poultry segment. The rising demand for eggs and poultry meat will boost the demand for poultry feed products. The increasing number of product launches will also fuel the growth of the animal feed market in this segment.

  • APAC was the largest market for animal feed in 2019,

Ludovic Blanquet Joins smartTrade as Chief Product and Strategic Planning Officer

The appointment will help shape smartTrade’s vision to deliver the leading cross-asset eTrading solution for its customers.

smartTrade Technologies today announces that Ludovic Blanquet has joined as Chief Product and Strategic Planning Officer. Ludovic will support smartTrade to deliver world class integrated eTrading solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005005/en/

Ludovic Blanquet – Chief Product and Strategic Planning Officer smartTrade Technologies (Photo: smartTrade Technologies)

Ludovic brings 20 years of industry experience to the role. He joins from Finastra where he was the Global Head of Product Strategy across its five lines of business. Prior to this, he built Credit Agricole APAC’s global equities trading platform and was APAC regional director for SmartStream, a corporate banking software vendor. Ludovic has experience working across multiple international markets having lived in Tokyo, London and Singapore during his career.

Ludovic will help shape smartTrade’s vision to deliver the leading cross-asset eTrading solution, capitalising on its market leading eFX LiquidityFX (LFX) cloud offering. Now based in London, Ludovic will lead a team of strategy and product managers responsible for designing and delivering on the future product roadmap in collaboration with smartTrade’s ecosystem of customers, partners, and liquidity providers.

David Vincent, CEO, smartTrade said, “Drawing on his business leadership experience, Ludovic will provide fresh insights to our product priorities as we help our clients and the wider industry to further modernise capital markets technology. In this new era, staying ahead of the market structure and technology evolution is more important than ever to help market participants seeking higher returns.”

Ludovic Blanquet said, “smartTrade is uniquely positioned to support the digitisation of trading across all asset classes. LFX end-to-end solution is a reliable, recognised leader delivering peace of mind to its clients – and this has certainly been tested in recent

Ex-Facebook executive says company made its product as addictive as cigarettes

Tech companies are coming under increasing pressure to address digital addiction. During a recent House committee hearing on the dangers of social media, former Facebook executive Tim Kendall told Congress that the company intentionally made its product as addictive as cigarettes.

Kendall, CEO of time-management app Moment and former director of monetization for Facebook, told the hearing held by the House Committee on Energy and Commerce: “Tobacco companies initially just sought to make nicotine more potent. But eventually that wasn’t enough to grow the business as fast as they wanted. And so they added sugar and menthol to cigarettes so you could hold the smoke in your lungs for longer periods, At Facebook, we added status updates, photo tagging, and likes.”

During an interview on CBSN, Kendall told CBS News’ Lana Zak that it all boils down to the social media giant’s advertising-based business model, in which the “objective is to get more people to pay attention to your product and to pay attention longer each and every day.”

“So what’s happened is you basically have an advertising business model that’s combined with just ever-growing, ever-more intelligent technology, and that combination is really potent,” said Kendall. “What it’s leading to is a product that’s just fundamentally addictive for people, and it’s causing all kinds of mental health issues, and I think it’s eroding aspects of society.”

While users attacking one another on social media is nothing new, Kendall believes social media sites are tearing people apart very quickly.  

“At the very least, we have eroded our collective understanding — at worst, I fear we are pushing ourselves to the brink of a civil war,” he said during the hearing.

With just a little over a month until Election Day, there have been serious concerns raised over Facebook’s role in

Neuromodulation Pioneer WISE Closes EUR 15M Series C Financing Round to Launch Second Product, SCS EXPERT, for Chronic Pain

  • SCS EXPERT is the first expandable percutaneous lead for neuromodulation treatment for chronic pain

  • New investors, led by CDP Venture Capital, and including Indaco Ventures I and EUREKA! Venture, join existing participating investors in financing round

  • Adds to EUR 2.3M grant earlier in 2020 from the European Commission to launch SCS EXPERT

WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led by CDP Venture Capital SGR, and including Indaco Ventures I Fund and EUREKA! Venture SGR, joined existing investors participating in this round – Principia SGR, New Frontier, Atlante Seed and Atlante Ventures (funds managed by Indaco Venture Partners SGR), High Tech Gründerfonds and F3F.

The proceeds will be partially used to accelerate the development of the Company’s second product, SCS EXPERT (EXpandable PERcuTaneous), a percutaneously implantable multi-column paddle lead for Spinal Cord Stimulation (SCS). The funds will also support the upcoming launch of its first product, WISE Cortical Strip (WCS), a single use medical device for IntraOperative Neurophysiological Monitoring during brain tumor and epilepsy surgeries, which is anticipating the granting of its CE mark.

This financing adds to the recent European Commission grant of EUR 2.3 million given to WISE in July 2020, to support the development and launch of SCS EXPERT within the EIC Accelerator program of Horizon 2020.

We are delighted with the support we have received for our latest funding round and welcome our new investors,” said Luca Ravagnan, CEO at WISE. “With this additional funding, we will be able to accelerate our plans to launch SCS EXPERT, as we make progress toward FDA clearance and market launch.”

He added, “With support from our engaged investors,